Sznitman S, Behar Y, Dicker-Oren S, Shochat T, Meiri D, Butto N
Psychopharmacology (Berl). 2025; 242(3):545-561.
PMID: 39825910
PMC: 11861408.
DOI: 10.1007/s00213-024-06704-8.
Irrmischer M, Puxty D, Yildirim B, Deijen J, Engelbregt H
Psychopharmacology (Berl). 2025; 242(4):725-740.
PMID: 39775022
PMC: 11890248.
DOI: 10.1007/s00213-024-06733-3.
Leistenschneider G, Majic T, Reiche S, Riemer T
Sci Rep. 2024; 14(1):32159.
PMID: 39741155
PMC: 11688453.
DOI: 10.1038/s41598-024-82216-x.
Koning E, Chaves C, Kirkpatrick R, Brietzke E
J Eat Disord. 2024; 12(1):214.
PMID: 39731144
PMC: 11673730.
DOI: 10.1186/s40337-024-01185-8.
Zahid Z, Sultan Z, Krause B, Wenthur C, Pearce R, Banks M
Psychedelic Med (New Rochelle). 2024; 2(3):166-177.
PMID: 39669671
PMC: 11633440.
DOI: 10.1089/psymed.2023.0061.
Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.
da Costa Goncalves K, de Tavares V, de Morais Barros M, de Brito A, Cavalcanti-Ribeiro P, Palhano-Fontes F
Eur Arch Psychiatry Clin Neurosci. 2024; .
PMID: 39467856
DOI: 10.1007/s00406-024-01925-6.
Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey.
Stroud J, Rice C, Orsini A, Schlosser M, Lee J, Mandy W
Psychopharmacology (Berl). 2024; 242(2):373-387.
PMID: 39367164
DOI: 10.1007/s00213-024-06685-8.
Predicting the Hallucinogenic Potential of Molecules Using Artificial Intelligence.
Urbina F, Jones T, Harris J, Snyder S, Lane T, Ekins S
ACS Chem Neurosci. 2024; 15(16):3078-3089.
PMID: 39092989
PMC: 11338697.
DOI: 10.1021/acschemneuro.4c00405.
Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.
Basedow L, Majic T, Hafiz N, Algharably E, Kreutz R, Riemer T
Sci Rep. 2024; 14(1):14782.
PMID: 38926480
PMC: 11208433.
DOI: 10.1038/s41598-024-65391-9.
Effects of Psychedelics in Older Adults: A Prospective Cohort Study.
Kettner H, Roseman L, Gazzaley A, Carhart-Harris R, Pasquini L
Am J Geriatr Psychiatry. 2024; 32(9):1047-1059.
PMID: 38849218
PMC: 11316630.
DOI: 10.1016/j.jagp.2024.05.007.
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
Atiq M, Baker M, Vande Voort J, Vargas M, Choi D
Psychopharmacology (Berl). 2024; .
PMID: 38743110
DOI: 10.1007/s00213-024-06599-5.
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).
Wolff M, Evens R, Mertens L, Schmidt C, Beck J, Rutrecht H
J Psychopharmacol. 2024; 38(5):432-457.
PMID: 38742761
PMC: 11102652.
DOI: 10.1177/02698811241249698.
Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies.
Armstrong M, Castellanos J, Christie D
Front Pain Res (Lausanne). 2024; 5:1346053.
PMID: 38706873
PMC: 11066302.
DOI: 10.3389/fpain.2024.1346053.
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Zaretsky T, Jagodnik K, Barsic R, Antonio J, Bonanno P, MacLeod C
Curr Neuropharmacol. 2024; 22(4):636-735.
PMID: 38284341
PMC: 10845102.
DOI: 10.2174/1570159X22666231027111147.
Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists.
Gren J, Tyls F, Lasocik M, Kiraly C
Front Psychol. 2023; 14:1054692.
PMID: 37904908
PMC: 10613493.
DOI: 10.3389/fpsyg.2023.1054692.
The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression.
Buchborn T, Kettner H, Kartner L, Meinhardt M
Front Neurosci. 2023; 17:1232459.
PMID: 37869510
PMC: 10587586.
DOI: 10.3389/fnins.2023.1232459.
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression.
Garel N, Drury J, Thibault Levesque J, Goyette N, Lehmann A, Looper K
Front Psychiatry. 2023; 14:1268832.
PMID: 37795512
PMC: 10546328.
DOI: 10.3389/fpsyt.2023.1268832.
History repeating: guidelines to address common problems in psychedelic science.
van Elk M, Fried E
Ther Adv Psychopharmacol. 2023; 13:20451253231198466.
PMID: 37766730
PMC: 10521293.
DOI: 10.1177/20451253231198466.
Psilocybin for the treatment of anorexia nervosa.
Majic T, Ehrlich S
Nat Med. 2023; 29(8):1906-1907.
PMID: 37488290
DOI: 10.1038/s41591-023-02458-6.
Harnessing placebo: Lessons from psychedelic science.
Pronovost-Morgan C, Hartogsohn I, Ramaekers J
J Psychopharmacol. 2023; 37(9):866-875.
PMID: 37392012
PMC: 10481630.
DOI: 10.1177/02698811231182602.